Clinical Study

A081105- Randomized Study Of Erlotinib Vs Observation In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (Nscls)

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is To assess whether adjuvant therapy with erlotinib will result in improved overall survival over observation for patients with completely resected stage IB-IIIA EGFR mutant NSCLC following complete resection and standard post-operative therapy.

Criteria:

To Be Eligible: Previously Registered To A151216, Must Have Early Stage Nsclc, Age 18 Or Older, Nonpregnant/Nonlactating

Keywords:

Lung Cancer, Nsclc, Cancer, Lung

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.